The preparation of an unprecedented series of nucleobase modified 3-fluoro-2-(phosphonomethoxy)propyl (FPMP) acyclic nucleosides in both their (R) and (S) enantiomerically pure forms is described. The synthesis focuses on a Mitsunobu alkylation reaction to construct the CÀ N(9) bond between a chiral fluorinated side-chain residue and 6-or 7-modified guanine analogs. Prodrugs of FPMP-7-deazaguanine were also synthesized by derivatization of the corresponding phosphonic acid functionality with (bis)diamyl aspartate amidate groups, leading to moderate activity against human immunodeficiency virus type 1 (HIV-1). of such modification on the antiviral activity of the resulting FPMP derivatives as well as the efficiency of the key Mitsunobu alkylation. Figure 1. Examples of purine modified acyclic nucleoside analogs relevant to this study. Scheme 1. Synthesis of (R)/(S)-fluorinated acyclic phosphonate acids 5a/b. Reagents and conditions: a) Ph 3 P, DIAD, THF, r.t., 24 h; b) THF/H 2 O, reflux, 24 h; c) Et 3 N, DMF, 100°C, 4 h; d) TMSBr, 2,6-lutidine, MeCN, r.t., 12 h. Scheme 2. Synthesis of (R)/(S)-fluorinated acyclic phosphonate acids 11a/b and 14a/b. Reagents and conditions: a) PivCl, pyridine, r.t., 3 h; b) Selectfluor, MeCN, 50°C, 30 min; c) Ph 3 P, DIAD, 2a/b, THF, r.t., 24 h; d) (i) DABCO, K 2 CO 3 , dioxane/H 2 O, 90°C, 3 h; (ii) NH 3 / MeOH, r.t., 12 h; e) TMSBr, 2,6-lutidine, MeCN, r.t., 12 h.